Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023) itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
SAN DIEGO, Sept. 26, 2023 Travere Therapeutics, Inc. today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study evaluating the potential.
Travere Therapeutics (TVTX) Reports Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI Demonstrating Long-Term Kidney Function Preservation streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
FILSPARI® achieved a clinically meaningful difference vs. irbesartan in eGFR total slope [p= 0.058] and eGFR chronic slope [p=0.037]. Patients treated with FILSPARI over two years exhibited one of.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.